Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Use of under-the-skin efgartigimod now approved for gMG in Japan

An under-the-skin or subcutaneous injection formulation of efgartigimod has been approved in Japan for use by adults with generalized myasthenia gravis (gMG) who do not sufficiently respond to first-line treatment with steroids or non-steroidal immunosuppressive therapies. In Japan, the now-approved therapy — efgartigimod alfa and hyaluronidase-qvfc — will be…

Cell therapy KYV-101 put on FDA fast track as MG treatment

KYV-101, an experimental cell therapy for myasthenia gravis (MG) in development by Kyverna Therapeutics, has been granted fast track status by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that have the potential to improve care for serious illnesses. The designation is…

Under-the-skin Vyvgart approved in Europe for AChR-positive gMG

A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) has been approved by the European Commission for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-causing antibody. This subcutaneous (under-the-skin) formulation now can be…

Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG

The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under the brand name Zilbrysq, for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). With this approval, Zilbrysq has now become the…